Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CXCR3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CXCR3 N-terminal ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed. |
View CXCR3 Products |
| Gene Delivery | CXCR3/CXCR3B Promise-ORF / Lentivirus Full-length ORF for stable cell line construction. Perfect for GPCR conformation-dependent assays. |
View CXCR3 Products |
| Benchmark Ab | Anti-CXCR3 Recombinant Antibody Recombinant positive control derived from clinical-grade benchmarks. |
View CXCR3 Products |
| Validator | CXCR3 siRNA Set For knockdown verification in functional assays. |
View CXCR3 Products |
| Related Target A | CXCL10 (IP-10) Primary chemokine ligand driving CXCR3-mediated chemotaxis in inflammatory sites. |
View CXCL10 Products |
| Related Target B | CXCR4 Homologous GPCR used for selectivity and off-target safety screening panels. |
View CXCR4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational GPCR Integrity | High-titer Lentivirus for stable overexpression in HEK293/CHO, preserving native 7-transmembrane conformation. |
| Isoform Selectivity (CXCR3-A vs CXCR3-B) | Sequence-verified ORF vectors and custom-designed N-terminal antigens matching specific splice variants. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration. |
| False Positives | Validated siRNA sets included for target-specific knockdown verification. |
Live CXCR3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CXCR3 therapeutics is intensifying, with major players shifting focus from traditional small-molecule antagonists to highly selective monoclonal antibodies and bispecific formats. CXCR3 (CD183) is a G protein-coupled receptor (GPCR) that exists in major splice variants: CXCR3-A (mediating chemotaxis and cellular proliferation) and CXCR3-B (mediating angiostasis and apoptosis). As first-generation small-molecule therapies reach clinical milestones in autoimmune diseases like vitiligo, inflammatory bowel disease (IBD), and lupus, the next wave of R&D is targeting the tumor microenvironment. By modulating CXCR3, therapies aim to recruit CXCR3+ T cells and NK cells into "cold" tumors, turning them "hot" to synergize with PD-1/PD-L1 checkpoint inhibitors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Antagonists | Amgen, Sanofi, Bristol Myers Squibb | Psoriasis, Vitiligo, Rheumatoid Arthritis | Calcium Flux & Chemotaxis Assays (Requires Lentivirus-driven stable cell lines) |
| Monoclonal Antibodies (mAbs) | Eli Lilly, Pfizer | Inflammatory Bowel Disease, Transplant Rejection | Epitope Mapping & Binding Affinity (Requires high-purity N-terminal ECD-Fc proteins) |
| Bispecific / Cell Therapies | Innovative Biotechs, Academic Centers | Solid Tumors (T-cell homing) | In vitro migration and cross-reactivity screening (Requires functional ligand proteins like CXCL10) |